Engineering nanomedicines to inhibit hypoxia-inducible Factor-1 for cancer therapy.

Xiaojuan Zhang, Chuanchuan He, Guangya Xiang

Cancer letters 2022 Apr 01

filter terms:

Hypoxia-inducible factor-1 (HIF-1), an essential promoter of tumor progression, has attracted increasing attention as a therapeutic target. In addition to hypoxic cellular conditions, HIF-1 activation can be triggered by cancer treatment, which causes drug tolerance and therapeutic failure. To date, a series of effective strategies have been explored to suppress HIF-1 function, including silencing the HIF-1α gene, inhibiting HIF-1α protein translation, degrading HIF-1α protein, and inhibiting HIF-1 transcription. Furthermore, nanoparticle-based drug delivery systems have been widely developed to improve the stability and pharmacokinetics of HIF-1 inhibitors or achieve HIF-1-targeted combination therapies as a nanoplatform. In this review, we summarize the current literature on nanomedicines targeting HIF-1 to combat cancer and discuss their potential for future development. Copyright © 2022. Published by Elsevier B.V.

Citation

Xiaojuan Zhang, Chuanchuan He, Guangya Xiang. Engineering nanomedicines to inhibit hypoxia-inducible Factor-1 for cancer therapy. Cancer letters. 2022 Apr 01;530:110-127